Table 1.

Clinical characteristics of the three CLL cohorts.

	Cohort 1 (‘early’)	Cohort 2 (‘high-risk’)	Cohort 3 (‘ibrutinib-treated’)
n	44	42	25
Treatment naïve, %	100	100	52
High-risk, %	41	100	84
Median age	68	60	68
M, %	48	79	44
Binet B + C, %	9	86	96
WHO 0, %	80	57	ND
M-IGHV, %	57	14	40
del(17p), %	2	26	48
del(11q), %	7	15	24
Tri12, %	5	23	8
Median β2m	191	351	348.5
Median WBC/ALC	27	91	72 (ALC)

%: percentage; n: number; High-risk: (del(17p), del(11q), t(12) and/or unmutated IGHV); M: male gender; M-IGHV: mutated IGHV; del(17p): deletion of the short arm of chromosome17; del(11q): deletion of the long arm of chromosome 11; Tri12: Trisomy of chromosome 12; β2m: beta 2 microglobulin; WBC: white-blood cell count; ALC: absolute lymphocyte count. FISH categories are restricted to those defining high risk CLL.